

Prostate Cancer

Research Analysts

Lee Kalowski
212 325 9683
lee.kalowski@credit-suisse.com

Catherine J. Arnold
212 538 6225
catherine.j.arnold@credit-suisse.com

Ravi Mehrotra PhD
212 325 3487
ravi.mehrotra@credit-suisse.com

Ari Jahja
212 325 0767
ariyanto.jahja@credit-suisse.com

Ronak H. Shah, Pharm.D., CFA
212 325 9799
ronak.shah@credit-suisse.com

Koon Ching PhD
212 325 6286
koon.ching@credit-suisse.com

COMMENT

Implications of Zytiga's Pre-Chemo Approval

- **JNJ's Zytiga received pre-chemo approval on December 10th (see our note "Zytiga pre-chemo approved: still no OS").** There was considerable speculation as to whether Zytiga would hit OS significance with data updated since its presentations at ASCO and ESMO this year. We fully expected FDA to approve Zytiga for pre-chemo use even without statistically significant OS data, as was indeed the case. Notably, the label does include an update to the OS data, but statistical significance was not achieved.
- **Overall survival looks incrementally worse for Zytiga – which is good for Xtandi -- though we don't think it changes how the products will be used.** The OS difference was only 5.2 months, which is lower than what we (and probably most) were expecting. This missed significance with a p-value of 0.0151 (Exhibit 1). The placebo arm also saw median OS increase to 30 months, worsening the HR from 0.75 to 0.79. (Exhibit 2). The data is a little puzzling, but between the strong OS trend, the robust rPFS data (HR of 0.43 on a median treatment duration of 14 months) and the robust OS benefit in the "301" trial, we don't think the update changes Zytiga's profile all that much or even how it is likely to be used.
- **The tolerability profile looks similar to what was seen in the "301" trial.** As was the case in the "301" trial, Zytiga is associated with liver function abnormalities in the pre-chemo setting, underscoring the importance of regular LFT monitoring, as has been outlined in the label (Exhibit 3). Cardiac failure was also higher with Zytiga (now 2.1% vs 0.7% on placebo). And, of course, with the approval in the pre-chemo setting, Zytiga is tied to longer-term use of prednisone (all adverse events from the label are shown in Exhibit 4).
- **The approval now marks the first meaningful entry into the urology segment of the prostate cancer market since DNDN's Provenge.** As per JNJ's Q3 call, about 30% of Zytiga has been in the pre-chemo setting (the setting for which Zytiga was just approved), but uptake by urologists has been negligible, at least per IMS data. With this approval, we now expect a more significant push into the urology segment of the market.

(bullets continue on next page)

AMERIGEN 1044

DISCLOSURE APPENDIX CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, INFORMATION ON TRADE ALERTS, ANALYST MODEL PORTFOLIOS AND THE STATUS OF NON-U.S ANALYSTS. US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

- **While MDVN (OP, TP: \$73) is not disclosing how it might change its own statistical plan for its pre-chemo “PREVAIL” trial, the company is confirming that it will wait for OS.** This is in-line with our expectations and, frankly, makes sense, given that (1) Xtandi has a relatively long patent life (2) it offers the potential for an OS comparative advantage vs Zytiga, especially if that product goes off-patent in around four years and (3) makes market entry for downstream competitors all the more challenging. Our best guess is that PREVAIL is likely to report out in 2H’13 – and we expect positive results from that trial.
- **Assuming PREVAIL is positive, National Comprehensive Cancer Network (NCCN) guidelines likely will put Xtandi ahead of Zytiga.** As we noted in our email on December 5th (“NCCN Prostate Cancer Guidelines Updated: Allows for Xtandi Pre-Chemo Use”), Xtandi received in the pre-chemo setting a category 2a (“lower-level evidence”), which is the same as Zytiga, despite the “302” data results (both products are category 1 (“high-level evidence”) in the post-chemo setting). Assuming PREVAIL is positive on OS, we would expect Xtandi to move to “1” – the same as Provenge – while Zytiga is likely to remain where it is.
- **We are not changing our Xtandi forecasts at this time.** Between what we see as more favorable tolerability and safety, the lack of required prednisone and likely better OS data, we continue to believe that Xtandi will capture a larger portion of the post and pre-chemo markets (we model 70% market share going to Xtandi vs Zytiga). We continue to believe that PREVAIL will show a treatment duration of at least the 14 months seen in the Zytiga “302” trial, resulting in upside from current levels.
- **For DNDN (N, TP: \$4), the Zytiga approval marks the imminent entry of a competitor in the pre-chemo (urology) setting.** But overall, the timing and nature of the approval is in-line with our expectations. Last quarter saw a substantial decline at the academic setting (-25%) and we don’t think this approval and label is likely to change that one way or another. We continue to believe that Provenge can be used in a niche setting of the mCRPC market – i.e. very slowly progressing asymptomatic mCRPC patients – although it remains to be seen what percentage actually fits into this category. Crucial for Provenge’s future will be for DNDN to finally gain a foothold within the community (and especially community urology) setting and JNJ’s push here won’t make it any easier for DNDN. We are not changing estimates at this time – we forecast flattish revenues in 2013 overall vs 2012, with some growth thereafter.
- **For JNJ (N, TP: \$71):** the Zytiga overall survival data is a slight disappointment, however, our (post-2014) Zytiga forecast already implies a competitive benefit for Xtandi secondary to not requiring prednisone on board. The smaller than expected OS benefit now leaves room for Xtandi to have a competitive benefit greater than already projected once PREVAIL reads out in 2H’13. In-line with this, a key element of our Neutral rating on JNJ is predicated on the fact that we expect notable competition to emerge for several key therapeutic areas in the next 12 months, keeping the stock range bound.

Exhibit 1: OS Data from Label and as Presented at ASCO 2012

Approved Label			Data Presented at ASCO - June 2012		
Overall Survival	Zytiga (N= 546)	Placebo (N=542)	Overall Survival	Zytiga (N= 546)	Placebo (N=542)
Deaths	200	234	Deaths		
Median Survival	35.3	30.1	Median Survival	NR	27.2
p-value	0.0151		p-value	0.0097	
Hazard Ratio	0.792		Hazard Ratio	0.75	

Source: Company data, Credit Suisse estimates

Exhibit 2: OS Curves – From Label (Updated Data) and at ASCO

	0	3	6	9	12	15	18	21	24	27	30	33	36
Zytiga-updated	546	538	524	503	482	452	421	393	333	175	68	15	0
Placebo-updated	542	534	508	492	465	437	400	361	283	153	67	9	0
Zytiga-ASCO	546	538	524	503	482	452	412	258	120	27	0	0	
Placebo-ASCO	542	534	509	493	465	437	387	237	106	25	2	0	

Source: Company data, Credit Suisse estimates

Exhibit 3: Liver Function Abnormalities From Label

	"301"		"302"	
	All Grades	Grade 3-4	All Grades	Grade 3-4
High ALT	30.6	2.1	41.9	6.1
High AST	11.1	1.4	37.3	3.1
Total	41.7	3.5	79.2	9.2

Source: Company data, Credit Suisse estimates

Exhibit 4: Zytiga AEs from Approved Label

	Zytiga - "301"		Zytiga - "302"	
	All Grades	Grade 3-4	All Grades	Grade 3-4
Joint Swelling/discomfort	29.5	4.2	Fatigue	39.1 2.2
Muscle Discomfort	26.2	3.0	Edema	25.1 0.4
Edema	26.7	1.9	Pyrexia	8.7 0.6
Hot flush	19.0	0.3	Joint swelling/discomfort	30.3 2.0
Hypertension	8.5	1.3	Groin pain	6.6 0.4
Diarrhea	17.6	0.6	Constipation	23.1 0.4
Dyspepsia	6.1	0.0	Diarrhea	21.6 0.9
Urinary tract infection	11.5	2.1	Dyspepsia	11.1 0.0
Upper respiratory tract	5.4	0.0	Hot flush	22.3 0.2
Cough	10.6	0.0	Hypertension	21.6 3.9
Urinary frequency	7.2	0.3	Cough	17.3 0.0
Nocturia	6.2	0.0	Dyspnea	11.8 2.4
Fractures	5.9	1.4	Insomnia	13.5 0.2
Arrhythmia	7.2	1.1	Contusion	13.3 0.0
Chest pain or chest discomfort	3.8	0.5	Falls	5.9 0.0
Cardiac failure	2.3	1.9	Upper respiratory tract	12.7 0.0
			Nasopharyngitis	10.7 0.0
			Hematuria	10.3 1.3
			Rash	8.1 0.0

Source: Company data, Credit Suisse estimates

Companies Mentioned (Price as of 10-Dec-2012)

Dendreon Corp. (DNDN.OQ, \$5.04, NEUTRAL[V], TP \$4.0)
Johnson & Johnson (JNJ.N, \$70.6, NEUTRAL, TP \$71.0)
Medivation (MDVN.OQ, \$55.33, OUTPERFORM[V], TP \$73.0)

Disclosure Appendix

Important Global Disclosures

Lee Kalowski, Catherine J. Arnold, Ravi Mehrotra PhD, each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

Price and Rating History for Dendreon Corp. (DNDN.OQ)

DNDN.OQ	Closing Price	Target Price	
Date	(US\$)	(US\$)	Rating
02-May-11	42.81	29.00	U *
03-Aug-11	35.84	22.00	N
09-Sep-11	11.42	14.00	
03-Nov-11	6.55	11.00	
30-Jan-12	14.17	14.00	
27-Feb-12	11.81	13.00	
08-May-12	8.75	12.00	
31-Jul-12	4.76	6.00	
05-Nov-12	4.17	4.00	


* Asterisk signifies initiation or assumption of coverage.



Price and Rating History for Johnson & Johnson (JNJ.N)

JNJ.N	Closing Price	Target Price	
Date	(US\$)	(US\$)	Rating
19-Jan-10	65.35	71.00	N
21-Apr-10	65.39	73.00	
04-Jun-10	58.01	69.00	
21-Jul-10	57.12	66.00	
27-Aug-10	57.60	65.00	
26-Jan-11	60.60	63.00	
18-Apr-11	60.46		R
11-Sep-12	68.20	70.00	N
25-Sep-12	69.32	71.00	


* Asterisk signifies initiation or assumption of coverage.



Price and Rating History for Medivation (MDVN.OQ)

MDVN.OQ	Closing Price	Target Price	
Date	(US\$)	(US\$)	Rating
30-Jan-12	27.44	76.00	O *
24-Feb-12	32.50	92.00	
29-Feb-12	32.76	90.00	
13-Mar-12	35.70		R
14-Mar-12	35.28	90.00	O
23-May-12	44.17	115.00	
04-Jun-12	40.82	122.00	
10-Aug-12	48.85	120.00	
04-Sep-12	54.60	149.00	
11-Nov-12	45.70	73.00	

* Asterisk signifies initiation or assumption of coverage.



The analyst(s) responsible for preparing this research report received Compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities

As of December 10, 2012 Analysts' stock rating are defined as follows:

Outperform (O) : The stock's total return is expected to outperform the relevant benchmark* over the next 12 months.

Neutral (N) : The stock's total return is expected to be in line with the relevant benchmark* over the next 12 months.

Underperform (U) : The stock's total return is expected to underperform the relevant benchmark* over the next 12 months.

**Relevant benchmark by region: As of 10th December 2012, Japanese ratings are based on a stock's total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. As of 2nd October 2012, U.S. and Canadian as well as European ratings are based on a stock's total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. For Latin American and non-Japan Asia stocks, ratings are based on a stock's total return relative to the average total return of the relevant country or regional benchmark; Australia, New Zealand are, and prior to 2nd October 2012 U.S. and Canadian ratings were based on (1) a stock's absolute total return potential to its current share price and (2) the relative attractiveness of a stock's total return potential within an analyst's coverage universe. For Australian and New Zealand stocks, 12-month rolling yield is incorporated in the absolute total return calculation and a 15% and a 7.5% threshold replace the 10-15% level in the Outperform and Underperform stock rating definitions, respectively. The 15% and 7.5% thresholds replace the +10-15% and -10-15% levels in the Neutral stock rating definition, respectively. Prior to 10th December 2012, Japanese ratings were based on a stock's total return relative to the average total return of the relevant country or regional benchmark.*

Restricted (R) : In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V] : A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts' sector weightings are distinct from analysts' stock ratings and are based on the analyst's expectations for the fundamentals and/or valuation of the sector* relative to the group's historic fundamentals and/or valuation:

Overweight : The analyst's expectation for the sector's fundamentals and/or valuation is favorable over the next 12 months.

Market Weight : The analyst's expectation for the sector's fundamentals and/or valuation is neutral over the next 12 months.

Underweight : The analyst's expectation for the sector's fundamentals and/or valuation is cautious over the next 12 months.

**An analyst's coverage sector consists of all companies covered by the analyst within the relevant sector. An analyst may cover multiple sectors.*

Credit Suisse's distribution of stock ratings (and banking clients) is:

Global Ratings Distribution

Rating	Versus universe (%)	Of which banking clients (%)
Outperform/Buy*	42%	(54% banking clients)
Neutral/Hold*	39%	(48% banking clients)
Underperform/Sell*	15%	(44% banking clients)
Restricted	3%	

**For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.*

Credit Suisse's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research_and_analytics/disclaimer/managing_conflicts_disclaimer.html

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

Price Target: (12 months) for Dendreon Corp. (DNDN.OQ)

Method: Our \$4 target price for DNDN is derived from a discounted cash flow modeled to 2020 using a terminal growth rate of -5% and a discount rate of 10%.

Risk: Upside risk to our \$4 target price include an accelerating launch trajectory, greater realized cost cutting than we model and successful commercialization in the EU; downside risk include: a launch trajectory below our expectations, greater competition than we anticipate and a higher cost base than we currently model.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.